Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study

Rosa T van der Kaaij, Hidde Jw Braam, Henk Boot, Maartje Los, Annemieke Cats, Cecile Grootscholten, Jan Hm Schellens, Arend Gj Aalbers, Alwin Dr Huitema, Catherijne Aj Knibbe, Djamila Boerma, Marinus J Wiezer, Bert van Ramshorst, Johanna W van Sandick, Rosa T van der Kaaij, Hidde Jw Braam, Henk Boot, Maartje Los, Annemieke Cats, Cecile Grootscholten, Jan Hm Schellens, Arend Gj Aalbers, Alwin Dr Huitema, Catherijne Aj Knibbe, Djamila Boerma, Marinus J Wiezer, Bert van Ramshorst, Johanna W van Sandick

Abstract

Background: Patients with gastric cancer and peritoneal carcinomatosis have a very poor prognosis; median survival is 3 to 4 months. Palliative systemic chemotherapy is currently the only treatment available in the Netherlands. Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has an established role in the treatment of peritoneal carcinomatosis originating from colorectal cancer, appendiceal cancer, and pseudomyxoma peritonei; its role in gastric cancer is uncertain. Currently, there is no consensus on the choice of chemotherapeutic agents used in HIPEC for gastric cancer.

Objective: The main objectives of this study are (1) to investigate the safety, tolerability, and feasibility of gastrectomy combined with cytoreductive surgery and HIPEC after systemic chemotherapy, as a primary treatment option for patients with advanced gastric cancer with tumor positive peritoneal cytology and/or limited peritoneal carcinomatosis; and (2) to determine the maximum tolerated dose (MTD) of intraperitoneal docetaxel in combination with a fixed dose of intraperitoneal oxaliplatin.

Methods: The PERISCOPE study is a multicenter, open label, phase I-II dose-escalation study. The MTD of docetaxel will be studied using a 3+3 design. Patients with locally advanced (cT3-cT4) gastric adenocarcinoma are eligible for inclusion if the primary gastric tumor is considered resectable, tumor positive peritoneal cytology and/or limited peritoneal carcinomatosis is confirmed by diagnostic laparoscopy/ laparotomy, and prior systemic chemotherapy was without disease progression. At laparotomy, cytoreductive surgery (complete removal of all macroscopically visible tumor deposits) and a total or partial gastrectomy with a D2 lymph node dissection is performed. An open HIPEC technique is used with 460mg/m2 hyperthermic oxaliplatin for 30 minutes (41°C to 42°C) followed by normothermic docetaxel for 90 minutes (37°C) in a dose that will be escalated per 3 patients (0, 50, 75, 100, 125, 150 mg/m2). The primary endpoint is treatment related toxicity.

Results: Patient accrual is ongoing and the first results are expected in 2017.

Conclusions: The PERISCOPE study will determine the safety, tolerability, and feasibility of gastrectomy combined with cytoreduction and HIPEC using oxaliplatin in combination with docetaxel after systemic chemotherapy as primary treatment option for gastric cancer patients with tumor positive peritoneal cytology and/or limited peritoneal carcinomatosis. This study will provide pharmacokinetic data on the intraperitoneal administration of oxaliplatin and docetaxel, including the MTD of intraperitoneal-administered docetaxel. These data are a prerequisite for the safe conduct of future HIPEC studies in patients with gastric cancer.

Trial registration: Netherlands Trial Registration (NTR): NTR4250; http://www.trialregister.nl/trialreg/admin/ rctview.asp?TC=4250 (Archived by WebCite at http://www.webcitation.org/6rWJONgkt).

Keywords: HIPEC; cytoreduction; docetaxel; gastrectomy; gastric cancer; hyperthermic intraperitoneal chemotherapy; oxaliplatin; peritoneal carcinomatosis.

Conflict of interest statement

Conflicts of Interest: None declared.

©Rosa T van der Kaaij, Hidde JW Braam, Henk Boot, Maartje Los, Annemieke Cats, Cecile Grootscholten, Jan HM Schellens, Arend GJ Aalbers, Alwin DR Huitema, Catherijne AJ Knibbe, Djamila Boerma, Marinus J Wiezer, Bert van Ramshorst, Johanna W van Sandick. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 13.07.2017.

Figures

Figure 1
Figure 1
Flowchart of the study design.
Figure 2
Figure 2
Peritoneal cancer index.
Figure 3
Figure 3
Simplified peritoneal cancer index.

References

    1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 06;355(1):11–20. doi: 10.1056/NEJMoa055531.
    1. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 01;30(19):2327–33. doi: 10.1200/JCO.2011.36.7136.
    1. Dassen AE, Dikken JL, Bosscha K, Wouters MW, Cats A, van de Velde CJ, Coebergh J, Lemmens VE. Gastric cancer: decreasing incidence but stable survival in the Netherlands. Acta Oncol. 2014 Jan;53(1):138–42. doi: 10.3109/0284186X.2013.789139.
    1. Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE, de Hingh IH. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014 Feb 01;134(3):622–8. doi: 10.1002/ijc.28373. doi: 10.1002/ijc.28373.
    1. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000 Jan 15;88(2):358–63.
    1. Yonemura Y, Endou Y, Shinbo M, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Mizuno M, Miura M, Ikeda M, Ikeda S, Nakajima G, Yonemura J, Yuuba T, Masuda S, Kimura H, Matsuki N. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol. 2009 Sep 15;100(4):311–6. doi: 10.1002/jso.21324.
    1. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006 Jan;7(1):69–76. doi: 10.1016/S1470-2045(05)70539-8.
    1. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008 Sep;15(9):2426–32. doi: 10.1245/s10434-008-9966-2.
    1. Matharu G, Tucker O, Alderson D. Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg. 2011 Sep;98(9):1225–35. doi: 10.1002/bjs.7586.
    1. Braam HJ, Schellens JH, Boot H, van Sandick JW, Knibbe CA, Boerma D, van Ramshorst B. Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer. Crit Rev Oncol Hematol. 2015 Sep;95(3):282–96. doi: 10.1016/j.critrevonc.2015.04.004.
    1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual, 7th Edition. New York, NY: Springer; 2011.
    1. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.
    1. Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FA. Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg. 2004 Jun;91(6):739–46. doi: 10.1002/bjs.4516.
    1. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995 Jan;221(1):29–42.
    1. Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, Yonemura Y, Ansaloni L. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014 Jan;40(1):12–26. doi: 10.1016/j.ejso.2013.10.019.
    1. Mi DH, Li Z, Yang KH, Cao N, Lethaby A, Tian JH, Santesso N, Ma B, Chen YL, Liu YL. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. Int J Hyperthermia. 2013;29(2):156–67. doi: 10.3109/02656736.2013.768359.
    1. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, Schiller D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011 Nov 01;104(6):692–8. doi: 10.1002/jso.22017.
    1. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002 Feb;13(2):267–72.
    1. Miyamoto K, Shimada T, Sawamoto K, Sai Y, Yonemura Y. Disposition kinetics of taxanes in peritoneal dissemination. Gastroenterol Res Pract. 2012;2012:963403. doi: 10.1155/2012/963403. doi: 10.1155/2012/963403.
    1. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001 Sep;37(13):1590–8.
    1. Sugarbaker PH, Ryan DP. Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol. 2012 Aug;13(8):e362–9. doi: 10.1016/S1470-2045(12)70210-3.
    1. Levine EA, Stewart JH 4th, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014 Apr;218(4):573–85. doi: 10.1016/j.jamcollsurg.2013.12.013.
    1. Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005 May;12(5):347–53. doi: 10.1245/ASO.2005.03.065.
    1. Wong J, Kelly KJ, Mittra A, Gonen M, Allen P, Fong Y, Coit D. RT-PCR increases detection of submicroscopic peritoneal metastases in gastric cancer and has prognostic significance. J Gastrointest Surg. 2012 May;16(5):889–96; discussion 896. doi: 10.1007/s11605-012-1845-2.
    1. Bonenkamp JJ, Songun I, Hermans J, van de Velde CJ. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg. 1996 May;83(5):672–4.
    1. Lee SD, Ryu KW, Eom BW, Lee JH, Kook MC, Kim YW. Prognostic significance of peritoneal washing cytology in patients with gastric cancer. Br J Surg. 2012 Mar;99(3):397–403. doi: 10.1002/bjs.7812.
    1. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD004064. doi: 10.1002/14651858.CD004064.pub3.

Source: PubMed

3
Předplatit